BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/8/2022 2:31:10 AM | Browse: 420 | Download: 1190
 |
Received |
|
2022-03-07 18:15 |
|
Peer-Review Started |
|
2022-03-07 18:16 |
|
First Decision by Editorial Office Director |
|
2022-04-17 20:51 |
|
Return for Revision |
|
2022-04-17 20:51 |
|
Revised |
|
2022-04-19 16:38 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-05-18 03:06 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-05-23 00:14 |
|
Articles in Press |
|
2022-05-23 00:14 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-05-31 07:43 |
|
Publish the Manuscript Online |
|
2022-06-08 02:31 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Awadhesh Kumar Singh and Ritu Singh |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Awadhesh Kumar Singh, MBBS, MD, Consultant Physician-Scientist, Intermediate Editor, Senior Postdoctoral Fellow, Senior Researcher, Department of Diabetes & Endocrinology, G.D Hospital & Diabetes Institute, 133A, Lenin Sarani, Kolkata 700013, West Bengal, India. draksingh_2001@yahoo.com |
| Key Words |
DPP-4 inhibitors; SGLT-2 inhibitors; GLP-1 receptor agonists; Cardiovascular outcomes; Renal outcomes |
| Core Tip |
Despite the newer anti-diabetic agents such as SGLT-2 inhibitors (SGLT-2Is) and GLP-1 receptor agonists have taken the center stage in the management of type 2 diabetes mellitus due to additional cardiac and renal benefits, the role of DPP-4 inhibitors (DPP-4Is) cannot be undermined. HbA1c lowering potential of DPP-4Is are nearly similar to SGLT-2Is and surprisingly larger in a background of modest baseline HbA1c compared with SGLT-2Is. Moreover, the HbA1c lowering abilities of SGLT-2Is are compromised with declining renal function while DPP-4Is reduce HbA1c favorably in people with chronic kidney disease regardless of impaired kidney functions. |
| Publish Date |
2022-06-08 02:31 |
| Citation |
Singh AK, Singh R. Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors. World J Diabetes 2022; 13(6): 466-470 |
| URL |
https://www.wjgnet.com/1948-9358/full/v13/i6/466.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v13.i6.466 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
